Enhancing Therapeutic Approaches in Glioblastoma with Pro-Oxidant Treatments and Synergistic Combinations: In Vitro Experience of Doxorubicin and Photodynamic Therapy

Autores
Cesca González, Bruno Agustín; Caverzan, Matias Daniel; Lamberti, María Julia; Ibarra, Luis Exequiel
Año de publicación
2024
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Glioblastoma (GBM) is an aggressive brain cancer characterized by significant molecularand cellular heterogeneity, which complicates treatment efforts. Current standard therapies, includingsurgical resection, radiation, and temozolomide (TMZ) chemotherapy, often fail to achieve longtermremission due to tumor recurrence and resistance. A pro-oxidant environment is involvedin glioma progression, with oxidative stress contributing to the genetic instability that leads togliomagenesis. Evaluating pro-oxidant therapies in brain tumors is crucial due to their potential toselectively target and eradicate cancer cells by exploiting the elevated oxidative stress levels inherentin these malignant cells, thereby offering a novel and effective strategy for overcoming resistance toconventional therapies. This study investigates the therapeutic potential of doxorubicin (DOX) andphotodynamic therapy (PDT) with Me-ALA, focusing on their effects on redox homeostasis. BasalROS levels and antioxidant gene expression (NFE2L2, CAT, GSR) were quantitatively assessed acrossGBM cell lines, revealing significant variability probably linked to genetic differences. DOX andPDT treatments, both individually and in combination, were analyzed for their efficacy in inducingoxidative stress and cytotoxicity. An in silico analysis further explored the relationship between genemutations and oxidative stress in GBM patients, providing insights into the molecular mechanismsunderlying treatment responses. Our findings suggest that pro-oxidant therapies, such as DOXand PDT in combination, could selectively target GBM cells, highlighting a promising avenue forimproving therapeutic outcomes in GBM.
Fil: Cesca González, Bruno Agustín. Universidad Nacional de Río Cuarto; Argentina
Fil: Caverzan, Matias Daniel. Universidad Nacional de Río Cuarto. Facultad de Ciencias Exactas Fisicoquímicas y Naturales. Instituto de Investigaciones en Tecnologías Energéticas y Materiales Avanzados. - Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Tecnologías Energéticas y Materiales Avanzados; Argentina
Fil: Lamberti, María Julia. Universidad Nacional de Río Cuarto. Facultad de Ciencias Exactas Fisicoquímicas y Naturales. Instituto de Biotecnología Ambiental y Salud - Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Biotecnología Ambiental y Salud; Argentina
Fil: Ibarra, Luis Exequiel. Universidad Nacional de Río Cuarto. Facultad de Ciencias Exactas Fisicoquímicas y Naturales. Instituto de Biotecnología Ambiental y Salud - Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Biotecnología Ambiental y Salud; Argentina
Materia
photodynamic therapy
chemotherapy;
glioblastoma
TP53 mutation
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/259076
Acceder
id CONICETDig_fc40dcc68203583e648935616596100b
oai_identifier_str oai:ri.conicet.gov.ar:11336/259076
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Enhancing Therapeutic Approaches in Glioblastoma with Pro-Oxidant Treatments and Synergistic Combinations: In Vitro Experience of Doxorubicin and Photodynamic TherapyCesca González, Bruno AgustínCaverzan, Matias DanielLamberti, María JuliaIbarra, Luis Exequielphotodynamic therapychemotherapy;glioblastomaTP53 mutationhttps://purl.org/becyt/ford/3.5https://purl.org/becyt/ford/3Glioblastoma (GBM) is an aggressive brain cancer characterized by significant molecularand cellular heterogeneity, which complicates treatment efforts. Current standard therapies, includingsurgical resection, radiation, and temozolomide (TMZ) chemotherapy, often fail to achieve longtermremission due to tumor recurrence and resistance. A pro-oxidant environment is involvedin glioma progression, with oxidative stress contributing to the genetic instability that leads togliomagenesis. Evaluating pro-oxidant therapies in brain tumors is crucial due to their potential toselectively target and eradicate cancer cells by exploiting the elevated oxidative stress levels inherentin these malignant cells, thereby offering a novel and effective strategy for overcoming resistance toconventional therapies. This study investigates the therapeutic potential of doxorubicin (DOX) andphotodynamic therapy (PDT) with Me-ALA, focusing on their effects on redox homeostasis. BasalROS levels and antioxidant gene expression (NFE2L2, CAT, GSR) were quantitatively assessed acrossGBM cell lines, revealing significant variability probably linked to genetic differences. DOX andPDT treatments, both individually and in combination, were analyzed for their efficacy in inducingoxidative stress and cytotoxicity. An in silico analysis further explored the relationship between genemutations and oxidative stress in GBM patients, providing insights into the molecular mechanismsunderlying treatment responses. Our findings suggest that pro-oxidant therapies, such as DOXand PDT in combination, could selectively target GBM cells, highlighting a promising avenue forimproving therapeutic outcomes in GBM.Fil: Cesca González, Bruno Agustín. Universidad Nacional de Río Cuarto; ArgentinaFil: Caverzan, Matias Daniel. Universidad Nacional de Río Cuarto. Facultad de Ciencias Exactas Fisicoquímicas y Naturales. Instituto de Investigaciones en Tecnologías Energéticas y Materiales Avanzados. - Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Tecnologías Energéticas y Materiales Avanzados; ArgentinaFil: Lamberti, María Julia. Universidad Nacional de Río Cuarto. Facultad de Ciencias Exactas Fisicoquímicas y Naturales. Instituto de Biotecnología Ambiental y Salud - Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Biotecnología Ambiental y Salud; ArgentinaFil: Ibarra, Luis Exequiel. Universidad Nacional de Río Cuarto. Facultad de Ciencias Exactas Fisicoquímicas y Naturales. Instituto de Biotecnología Ambiental y Salud - Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Biotecnología Ambiental y Salud; ArgentinaMolecular Diversity Preservation International2024-07info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/259076Cesca González, Bruno Agustín; Caverzan, Matias Daniel; Lamberti, María Julia; Ibarra, Luis Exequiel; Enhancing Therapeutic Approaches in Glioblastoma with Pro-Oxidant Treatments and Synergistic Combinations: In Vitro Experience of Doxorubicin and Photodynamic Therapy; Molecular Diversity Preservation International; International Journal of Molecular Sciences; 25; 14; 7-2024; 1-231422-0067CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.mdpi.com/1422-0067/25/14/7525info:eu-repo/semantics/altIdentifier/doi/10.3390/ijms25147525info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-15T15:00:09Zoai:ri.conicet.gov.ar:11336/259076instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-15 15:00:10.019CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Enhancing Therapeutic Approaches in Glioblastoma with Pro-Oxidant Treatments and Synergistic Combinations: In Vitro Experience of Doxorubicin and Photodynamic Therapy
title Enhancing Therapeutic Approaches in Glioblastoma with Pro-Oxidant Treatments and Synergistic Combinations: In Vitro Experience of Doxorubicin and Photodynamic Therapy
spellingShingle Enhancing Therapeutic Approaches in Glioblastoma with Pro-Oxidant Treatments and Synergistic Combinations: In Vitro Experience of Doxorubicin and Photodynamic Therapy
Cesca González, Bruno Agustín
photodynamic therapy
chemotherapy;
glioblastoma
TP53 mutation
title_short Enhancing Therapeutic Approaches in Glioblastoma with Pro-Oxidant Treatments and Synergistic Combinations: In Vitro Experience of Doxorubicin and Photodynamic Therapy
title_full Enhancing Therapeutic Approaches in Glioblastoma with Pro-Oxidant Treatments and Synergistic Combinations: In Vitro Experience of Doxorubicin and Photodynamic Therapy
title_fullStr Enhancing Therapeutic Approaches in Glioblastoma with Pro-Oxidant Treatments and Synergistic Combinations: In Vitro Experience of Doxorubicin and Photodynamic Therapy
title_full_unstemmed Enhancing Therapeutic Approaches in Glioblastoma with Pro-Oxidant Treatments and Synergistic Combinations: In Vitro Experience of Doxorubicin and Photodynamic Therapy
title_sort Enhancing Therapeutic Approaches in Glioblastoma with Pro-Oxidant Treatments and Synergistic Combinations: In Vitro Experience of Doxorubicin and Photodynamic Therapy
dc.creator.none.fl_str_mv Cesca González, Bruno Agustín
Caverzan, Matias Daniel
Lamberti, María Julia
Ibarra, Luis Exequiel
author Cesca González, Bruno Agustín
author_facet Cesca González, Bruno Agustín
Caverzan, Matias Daniel
Lamberti, María Julia
Ibarra, Luis Exequiel
author_role author
author2 Caverzan, Matias Daniel
Lamberti, María Julia
Ibarra, Luis Exequiel
author2_role author
author
author
dc.subject.none.fl_str_mv photodynamic therapy
chemotherapy;
glioblastoma
TP53 mutation
topic photodynamic therapy
chemotherapy;
glioblastoma
TP53 mutation
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.5
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Glioblastoma (GBM) is an aggressive brain cancer characterized by significant molecularand cellular heterogeneity, which complicates treatment efforts. Current standard therapies, includingsurgical resection, radiation, and temozolomide (TMZ) chemotherapy, often fail to achieve longtermremission due to tumor recurrence and resistance. A pro-oxidant environment is involvedin glioma progression, with oxidative stress contributing to the genetic instability that leads togliomagenesis. Evaluating pro-oxidant therapies in brain tumors is crucial due to their potential toselectively target and eradicate cancer cells by exploiting the elevated oxidative stress levels inherentin these malignant cells, thereby offering a novel and effective strategy for overcoming resistance toconventional therapies. This study investigates the therapeutic potential of doxorubicin (DOX) andphotodynamic therapy (PDT) with Me-ALA, focusing on their effects on redox homeostasis. BasalROS levels and antioxidant gene expression (NFE2L2, CAT, GSR) were quantitatively assessed acrossGBM cell lines, revealing significant variability probably linked to genetic differences. DOX andPDT treatments, both individually and in combination, were analyzed for their efficacy in inducingoxidative stress and cytotoxicity. An in silico analysis further explored the relationship between genemutations and oxidative stress in GBM patients, providing insights into the molecular mechanismsunderlying treatment responses. Our findings suggest that pro-oxidant therapies, such as DOXand PDT in combination, could selectively target GBM cells, highlighting a promising avenue forimproving therapeutic outcomes in GBM.
Fil: Cesca González, Bruno Agustín. Universidad Nacional de Río Cuarto; Argentina
Fil: Caverzan, Matias Daniel. Universidad Nacional de Río Cuarto. Facultad de Ciencias Exactas Fisicoquímicas y Naturales. Instituto de Investigaciones en Tecnologías Energéticas y Materiales Avanzados. - Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Tecnologías Energéticas y Materiales Avanzados; Argentina
Fil: Lamberti, María Julia. Universidad Nacional de Río Cuarto. Facultad de Ciencias Exactas Fisicoquímicas y Naturales. Instituto de Biotecnología Ambiental y Salud - Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Biotecnología Ambiental y Salud; Argentina
Fil: Ibarra, Luis Exequiel. Universidad Nacional de Río Cuarto. Facultad de Ciencias Exactas Fisicoquímicas y Naturales. Instituto de Biotecnología Ambiental y Salud - Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Biotecnología Ambiental y Salud; Argentina
description Glioblastoma (GBM) is an aggressive brain cancer characterized by significant molecularand cellular heterogeneity, which complicates treatment efforts. Current standard therapies, includingsurgical resection, radiation, and temozolomide (TMZ) chemotherapy, often fail to achieve longtermremission due to tumor recurrence and resistance. A pro-oxidant environment is involvedin glioma progression, with oxidative stress contributing to the genetic instability that leads togliomagenesis. Evaluating pro-oxidant therapies in brain tumors is crucial due to their potential toselectively target and eradicate cancer cells by exploiting the elevated oxidative stress levels inherentin these malignant cells, thereby offering a novel and effective strategy for overcoming resistance toconventional therapies. This study investigates the therapeutic potential of doxorubicin (DOX) andphotodynamic therapy (PDT) with Me-ALA, focusing on their effects on redox homeostasis. BasalROS levels and antioxidant gene expression (NFE2L2, CAT, GSR) were quantitatively assessed acrossGBM cell lines, revealing significant variability probably linked to genetic differences. DOX andPDT treatments, both individually and in combination, were analyzed for their efficacy in inducingoxidative stress and cytotoxicity. An in silico analysis further explored the relationship between genemutations and oxidative stress in GBM patients, providing insights into the molecular mechanismsunderlying treatment responses. Our findings suggest that pro-oxidant therapies, such as DOXand PDT in combination, could selectively target GBM cells, highlighting a promising avenue forimproving therapeutic outcomes in GBM.
publishDate 2024
dc.date.none.fl_str_mv 2024-07
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/259076
Cesca González, Bruno Agustín; Caverzan, Matias Daniel; Lamberti, María Julia; Ibarra, Luis Exequiel; Enhancing Therapeutic Approaches in Glioblastoma with Pro-Oxidant Treatments and Synergistic Combinations: In Vitro Experience of Doxorubicin and Photodynamic Therapy; Molecular Diversity Preservation International; International Journal of Molecular Sciences; 25; 14; 7-2024; 1-23
1422-0067
CONICET Digital
CONICET
url http://hdl.handle.net/11336/259076
identifier_str_mv Cesca González, Bruno Agustín; Caverzan, Matias Daniel; Lamberti, María Julia; Ibarra, Luis Exequiel; Enhancing Therapeutic Approaches in Glioblastoma with Pro-Oxidant Treatments and Synergistic Combinations: In Vitro Experience of Doxorubicin and Photodynamic Therapy; Molecular Diversity Preservation International; International Journal of Molecular Sciences; 25; 14; 7-2024; 1-23
1422-0067
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.mdpi.com/1422-0067/25/14/7525
info:eu-repo/semantics/altIdentifier/doi/10.3390/ijms25147525
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Molecular Diversity Preservation International
publisher.none.fl_str_mv Molecular Diversity Preservation International
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846083140421943296
score 13.22299

Publicaciones similares